Two countries – Two treatment strategies for rectal cancer

Radiotherapy and Oncology

Volumn 121, Issue 3, 2016, Pages 357-363

  Glimelius, Bengt ^a   Myklebust, Tor Åge ^b   Lundqvist, Kristina ^c   Wibe, Arne ^d   Guren, Marianne G ^e  

^a UPPSALA UNIVERSITY   (Sweden)

^b CANCER REGISTRY OF NORWAY   (Norway)

^c UMEÅ UNIVERSITY   (Sweden)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Local recurrence; Population data; Radiotherapy; Rectal cancer; Survival

Indexed keywords

ADULT; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CHEMORADIOTHERAPY; DISTANT METASTASIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORWAY; POSTOPERATIVE COMPLICATION; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RADICAL RESECTION; RECTUM CANCER; RECURRENCE RISK; SURGICAL MORTALITY; SURVIVAL; SWEDEN; TREATMENT OUTCOME; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT RADIOTHERAPY; COMPARATIVE STUDY; KAPLAN MEIER METHOD; MIDDLE AGED; NEOADJUVANT THERAPY; PREOPERATIVE CARE; PREVENTION AND CONTROL; PROCEDURES; PROFESSIONAL PRACTICE; RECTAL NEOPLASMS; REGISTER; STATISTICS AND NUMERICAL DATA; TRENDS; TUMOR RECURRENCE; UTILIZATION;

AGED; CHEMORADIOTHERAPY, ADJUVANT; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NORWAY; PREOPERATIVE CARE; PROFESSIONAL PRACTICE; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; REGISTRIES; SWEDEN; TREATMENT OUTCOME;

EID: 85006434766     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2016.11.010     Document Type: Article

References (43)

1. [1] Sebag-Montefiore, D., Stephens, R.J., Steele, R., et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373 (2009), 811–820.
2. [2] Glimelius, B., Multidisciplinary treatment of patients with rectal cancer: development during the past decades and plans for the future. Ups J Med Sci 117 (2012), 225–236.
3. [3] Swedish Rectal Cancer Trial, Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336 (1997), 980–987.
4. [4] Kapiteijn, E., Marijnen, C.A.M., Nagtegaal, I.D., et al. Preoperative radiotherapy in combination with total mesorectal excision improves local control in resectable rectal cancer. Report from a multicenter randomized trial. New Engl J Med 345 (2001), 638–646.
5. [5] Heald, R.J., Husband, E.M., Ryall, R.D., The mesorectum in rectal cancer surgery–the clue to pelvic recurrence?. Br J Surg 69 (1982), 613–616.
6. [6] Frykholm, G., Glimelius, B., Påhlman, L., Pre- or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum 36 (1993), 564–572.
7. [7] Sauer, R., Becker, H., Hohenberger, W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351 (2004), 1731–1740.
8. [8] Tveit, K.M., Guldvog, I., Hagen, S., et al. Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of dukes B and C rectal cancer. Br J Surg 84 (1997), 1130–1135.
9. [9] Martling, A.L., Holm, T., Rutqvist, L.E., et al. Effect of a surgical training programme on outcome of rectal cancer in the county of Stockholm. Lancet 356 (2000), 93–96.
10. [10] Wibe, A., Moller, B., Norstein, J., et al. A national strategic change in treatment policy for rectal cancer–implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum 45 (2002), 857–866.
11. [11] Påhlman, L., Bohe, M., Cedermark, B., et al. The Swedish rectal cancer registry. Br J Surg 94 (2007), 1285–1292.
12. [12] Guren, M.G., Korner, H., Pfeffer, F., et al. Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993–2010. Acta Oncol 54 (2015), 1714–1722.
13. [13] Dahlberg, M., Glimelius, B., Påhlman, L., Changing strategy for rectal cancer is associated with improved outcome. Br J Surg 86 (1999), 379–384.
14. [14] Kodeda, K., Johansson, R., Zar, N., et al. Time trends, improvements and national auditing of rectal cancer management over an 18-year period. Colorectal Dis 17 (2015), O168–O179.
15. [15] Nedrebo, B.S., Soreide, K., Eriksen, M.T., et al. Survival effect of implementing national treatment strategies for curatively resected colonic and rectal cancer. Br J Surg 98 (2011), 716–723.
16. [16] Tiselius, C., Gunnarsson, U., Smedh, K., et al. Patients with rectal cancer receiving adjuvant chemotherapy have an increased survival: a population-based longitudinal study. Ann Oncol 24 (2013), 160–165.
17. [17] Braendengen, M., Tveit, K.M., Berglund, Å., et al. A randomized phase III study (LARCS) comparing preoperative radiotherapy alone versus chemoradiotherapy in non-resectable rectal cancer. J Clin Oncol 26 (2008), 3687–3694.
18. [18] Pettersson, D., Cedermark, B., Holm, T., et al. Interim analysis of the stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 97 (2010), 580–587.
19. [19] Pettersson, D., Lorinc, E., Holm, T., et al. Tumour regression in the randomized stockholm III trial of radiotherapy regimens for rectal cancer. Br J Surg 102 (2015), 972–978.
20. [20] Hansen, M.H., Kjaeve, J., Revhaug, A., et al. Impact of radiotherapy on local recurrence of rectal cancer in Norway. Br J Surg 94 (2007), 113–118.
21. [21] Radu, C., Berglund, Å., Påhlman, L., et al. Short course preoperative radiotherapy with delayed surgery in rectal cancer–a retrospective study. Radiother Oncol 87 (2008), 343–349.
22. [22] Sakkestad, S.T., Olsen, B.C., Karliczek, A., et al. Validity of norwegian rectal cancer registry data at a major university hospital 1997–2005. Acta Oncol 54 (2015), 1723–1728.
23. [23] Jorgren, F., Johansson, R., Damber, L., et al. Validity of the Swedish rectal cancer registry for patients treated with major abdominal surgery between 1995 and 1997. Acta Oncol 52 (2013), 1707–1714.
24. [24] Valentini, V., Aristei, C., Glimelius, B., et al. Multidisciplinary rectal cancer management. Radiother Oncol 92 (2009), 148–163.
25. [25] Bujko, K., Nowacki, M.P., Nasierowska-Guttmejer, A., et al. Long-term results of a randomised trial comparing preoperative short-course radiotherapy vs preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93 (2006), 1215–1223.
26. [26] Ngan, S.Y., Burmeister, B., Fisher, R.J., et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with t3 rectal cancer: trans-tasman radiation oncology group trial 01.04. J Clin Oncol 30 (2012), 3827–3833.
27. [27] Cronin, K.A., Feuer, E.J., Cumulative cause-specific mortality for cancer patients in the presence of other causes: a crude analogue of relative survival. Stat Med 19 (2000), 1729–1740.
28. [28] Birgisson, H., Påhlman, L., Gunnarsson, U., et al. Late adverse effects of radiation therapy for rectal cancer–a systematic overview. Acta Oncol 46 (2007), 504–516.
29. [29] Pollack, J., Holm, T., Cedermark, B., et al. Late adverse effects of short-course preoperative radiotherapy in rectal cancer. Br J Surg 93 (2006), 1519–1525.
30. [30] Bruheim, K., Guren, M.G., Skovlund, E., et al. Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 76 (2010), 1005–1011.
31. [31] Dahlberg, M., Glimelius, B., Graf, W., et al. Preoperative irradiation affects the functional results after surgery for rectal cancer. Dis Colon Rectum 41 (1998), 543–549.
32. [32] Lange, M.M., Marijnen, C.A., Maas, C.P., et al. Risk factors for sexual dysfunction after rectal cancer treatment. Eur J Cancer 45 (2009), 1578–1588.
33. [33] Bruheim, K., Guren, M.G., Dahl, A.A., et al. Sexual function in males after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 76 (2010), 1012–1017.
34. [34] Bruheim, K., Tveit, K.M., Skovlund, E., et al. Sexual function in females after radiotherapy for rectal cancer. Acta Oncol 49 (2010), 826–832.
35. [35] Wiltink, L.M., Nout, R.A., Fiocco, M., et al. No increased risk of second cancer after radiotherapy in patients treated for rectal or endometrial cancer in the randomized TME, PORTEC-1, and PORTEC-2 trials. J Clin Oncol 33 (2015), 1640–1646.
36. [36] Martling, A., Smedby, K.E., Birgisson, H., et al. Risk of second primary cancer in patients treated with radiotherapy for rectal cancer. Br J Surg, 2016, 10.1002/bjs.10327 in press.
37. [37] Morris, E.J., Finan, P.J., Spencer, K., et al. Wide variation in the use of radiotherapy in the management of surgically treated rectal cancer across the English National Health Service. Clin Oncol (R Coll Radiol) 28 (2016), 522–531.
38. [38] Bernstein, T.E., Endreseth, B.H., Romundstad, P., et al. Circumferential resection margin as a prognostic factor in rectal cancer. Br J Surg 96 (2009), 1348–1357.
39. [39] Nilsson, P.J., van Etten, B., Hospers, G.A.P., et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer–the RAPIDO trial. BMC Cancer, 13, 2013, 279.
40. [40] Bujko, K., Wyrwicz, L., Rutkowski, A., et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol 27 (2016), 834–842.
41. [41] Sorbye, H., Cvancarova, M., Qvortrup, C., et al. Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Ann Oncol 24 (2013), 2354–2360.
42. [42] Breugom, A.J., Swets, M., Bosset, J.F., et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16 (2015), 200–207.
43. [43] Bujko, K., Glimelius, B., Valentini, V., et al. Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: a meta-analysis of randomized trials comparing surgery +/− a fluoropyrimidine and surgery + a fluoropyrimidine +/− oxaliplatin. Eur J Surg Oncol 41 (2015), 713–723.